
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (25): 3614-3623.DOI: 10.12114/j.issn.1007-9572.2025.0446
• Original Research • Previous Articles Next Articles
Received:2025-12-04
Revised:2026-07-09
Published:2026-09-05
Online:2026-08-11
Contact:
WU Shouling, YANG Xiuhong
通讯作者:
吴寿岭, 杨秀红
作者简介:作者贡献:
董澳、赵乃慧、欧文丽提出研究命题和设计方案;陈朔华、汪国栋、戴璐尧、刘灿章进行数据收集与整理;董澳、赵乃慧、欧文丽、陈朔华、汪国栋负责数据分析与解释;董澳、赵乃慧、欧文丽进行手稿起草;杨秀红、吴寿岭负责监督、写作、审稿和编辑,以及资金获取。
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2025.0446
| 项目 | Q1组(n=19 545) | Q2组(n=19 907) | Q3组(n=19 227) | Q4组(n=19 436) | 合计(n=78 115) | 检验统计量 | P值 |
|---|---|---|---|---|---|---|---|
| 年龄( | 49.0±12.5 | 49.9±11.8 | 51.0±11.4 | 50.4±10.9 | 50.1±11.7 | 103.29a | <0.001 |
| 性别[名(%)] | 860.08a | <0.001 | |||||
| 男 | 14 317(73.3) | 1 5824(79.5) | 15 678(81.5) | 16 486(84.8) | 62 305(79.8) | ||
| 女 | 5 228(26.7) | 4 083(20.5) | 3 549(18.5) | 2 950(15.2) | 15 810(20.2) | ||
| 饮酒[名(%)] | 7 730(39.5) | 7 288(36.6) | 7 556(39.3) | 8 196(42.2) | 30 770(39.4) | 127.58a | <0.001 |
| 吸烟[名(%)] | 6 650(34.0) | 6 693(33.6) | 6 983(36.3) | 7 579(39.0) | 27 905(35.7) | 156.44a | <0.001 |
| 体育锻炼[名(%)] | 2 843(14.5) | 2 899(14.6) | 2 891(15.0) | 2 840(14.6) | 11 473(14.7) | 2.51a | 0.470 |
| 受教育程度[名(%)] | 233.72a | <0.001 | |||||
| 高中及以上 | 5 038(25.8) | 4 044(20.3) | 3 926(20.4) | 4 093(21.1) | 17 101(21.9) | ||
| 高中以下 | 14 507(74.2) | 15 863(79.7) | 1 5301(79.6) | 15 343(78.9) | 61 014(78.1) | ||
| 高血压[名(%)] | 5 418(27.7) | 7 412(38.0) | 8 561(43.8) | 9 674(49.5) | 31 065(39.8) | 2 111.49 a | <0.001 |
| 糖尿病[名(%)] | 780(4.0) | 1 315(6.6) | 1 763(9.2) | 2 564(13.2) | 6 422(8.2) | 1 191.82a | <0.001 |
| 降压药[名(%)] | 953(4.9) | 1 456(7.3) | 2 038(10.6) | 2 473(12.7) | 6 920(8.9) | 874.61a | <0.001 |
| 降糖药[名(%)] | 223(1.1) | 326(1.6) | 480(2.5) | 567(2.9) | 1 596(2.0) | 189.80a | <0.001 |
| 调脂药[名(%)] | 84(0.4) | 134(0.7) | 169(0.9) | 252(1.3) | 639(0.8) | 97.20a | <0.001 |
| BMI( | 22.99±3.01 | 24.56±3.11 | 25.68±3.22 | 26.72±3.30 | 24.98±3.45 | 4 990.60b | <0.001 |
| UA( | 265.35±72.67 | 276.82±75.54 | 294.47±82.12 | 314.61±88.92 | 287.70±82.15 | 1 409.69b | <0.001 |
| WC( | 80.86±9.05 | 85.48±8.73 | 89.00±8.93 | 92.01±8.97 | 86.81±9.84 | 5 636.67b | <0.001 |
| WT( | 64.16±9.88 | 69.05±10.27 | 72.29±10.73 | 75.67±11.19 | 70.27±11.35 | 4 227.82b | <0.001 |
| DBP( | 80±11 | 82±11 | 84±12 | 86±12 | 83±12 | 1 037.71b | <0.001 |
| SBP( | 124±20 | 128±20 | 131±20 | 133±20 | 129±20 | 794.43b | <0.001 |
| FBG( | 5.13±1.22 | 5.32±1.36 | 5.49±1.57 | 5.74±1.90 | 5.42±1.55 | 542.82b | <0.001 |
| LDL-C( | 2.20±0.92 | 2.38±0.88 | 2.40±0.90 | 2.28±0.95 | 2.31±0.92 | 200.29b | <0.001 |
| HDL-C( | 1.75±0.42 | 1.57±0.35 | 1.46±0.33 | 1.35±0.34 | 1.53±0.39 | 4 273.16b | <0.001 |
| TG[M(P25,P75),mmol/L] | 0.70(0.57,0.84) | 1.07(0.91,1.24) | 1.49(1.26,1.76) | 2.64(2.06,3.73) | 1.25(0.87,1.89) | 2 8454.0c | <0.001 |
| TC( | 4.81±0.97 | 4.95±1.00 | 5.07±1.01 | 4.99±1.34 | 4.96±1.09 | 182.84b | <0.001 |
| hs-CRP[M(P25,P75),mg/L] | 0.57(0.20,1.70) | 0.70(0.28,1.91) | 0.89(0.34,2.30) | 1.07(0.42,2.70) | 0.80(0.30,2.15) | 20.40c | <0.001 |
Table 1 Baseline characteristics of the CMI quartile group population
| 项目 | Q1组(n=19 545) | Q2组(n=19 907) | Q3组(n=19 227) | Q4组(n=19 436) | 合计(n=78 115) | 检验统计量 | P值 |
|---|---|---|---|---|---|---|---|
| 年龄( | 49.0±12.5 | 49.9±11.8 | 51.0±11.4 | 50.4±10.9 | 50.1±11.7 | 103.29a | <0.001 |
| 性别[名(%)] | 860.08a | <0.001 | |||||
| 男 | 14 317(73.3) | 1 5824(79.5) | 15 678(81.5) | 16 486(84.8) | 62 305(79.8) | ||
| 女 | 5 228(26.7) | 4 083(20.5) | 3 549(18.5) | 2 950(15.2) | 15 810(20.2) | ||
| 饮酒[名(%)] | 7 730(39.5) | 7 288(36.6) | 7 556(39.3) | 8 196(42.2) | 30 770(39.4) | 127.58a | <0.001 |
| 吸烟[名(%)] | 6 650(34.0) | 6 693(33.6) | 6 983(36.3) | 7 579(39.0) | 27 905(35.7) | 156.44a | <0.001 |
| 体育锻炼[名(%)] | 2 843(14.5) | 2 899(14.6) | 2 891(15.0) | 2 840(14.6) | 11 473(14.7) | 2.51a | 0.470 |
| 受教育程度[名(%)] | 233.72a | <0.001 | |||||
| 高中及以上 | 5 038(25.8) | 4 044(20.3) | 3 926(20.4) | 4 093(21.1) | 17 101(21.9) | ||
| 高中以下 | 14 507(74.2) | 15 863(79.7) | 1 5301(79.6) | 15 343(78.9) | 61 014(78.1) | ||
| 高血压[名(%)] | 5 418(27.7) | 7 412(38.0) | 8 561(43.8) | 9 674(49.5) | 31 065(39.8) | 2 111.49 a | <0.001 |
| 糖尿病[名(%)] | 780(4.0) | 1 315(6.6) | 1 763(9.2) | 2 564(13.2) | 6 422(8.2) | 1 191.82a | <0.001 |
| 降压药[名(%)] | 953(4.9) | 1 456(7.3) | 2 038(10.6) | 2 473(12.7) | 6 920(8.9) | 874.61a | <0.001 |
| 降糖药[名(%)] | 223(1.1) | 326(1.6) | 480(2.5) | 567(2.9) | 1 596(2.0) | 189.80a | <0.001 |
| 调脂药[名(%)] | 84(0.4) | 134(0.7) | 169(0.9) | 252(1.3) | 639(0.8) | 97.20a | <0.001 |
| BMI( | 22.99±3.01 | 24.56±3.11 | 25.68±3.22 | 26.72±3.30 | 24.98±3.45 | 4 990.60b | <0.001 |
| UA( | 265.35±72.67 | 276.82±75.54 | 294.47±82.12 | 314.61±88.92 | 287.70±82.15 | 1 409.69b | <0.001 |
| WC( | 80.86±9.05 | 85.48±8.73 | 89.00±8.93 | 92.01±8.97 | 86.81±9.84 | 5 636.67b | <0.001 |
| WT( | 64.16±9.88 | 69.05±10.27 | 72.29±10.73 | 75.67±11.19 | 70.27±11.35 | 4 227.82b | <0.001 |
| DBP( | 80±11 | 82±11 | 84±12 | 86±12 | 83±12 | 1 037.71b | <0.001 |
| SBP( | 124±20 | 128±20 | 131±20 | 133±20 | 129±20 | 794.43b | <0.001 |
| FBG( | 5.13±1.22 | 5.32±1.36 | 5.49±1.57 | 5.74±1.90 | 5.42±1.55 | 542.82b | <0.001 |
| LDL-C( | 2.20±0.92 | 2.38±0.88 | 2.40±0.90 | 2.28±0.95 | 2.31±0.92 | 200.29b | <0.001 |
| HDL-C( | 1.75±0.42 | 1.57±0.35 | 1.46±0.33 | 1.35±0.34 | 1.53±0.39 | 4 273.16b | <0.001 |
| TG[M(P25,P75),mmol/L] | 0.70(0.57,0.84) | 1.07(0.91,1.24) | 1.49(1.26,1.76) | 2.64(2.06,3.73) | 1.25(0.87,1.89) | 2 8454.0c | <0.001 |
| TC( | 4.81±0.97 | 4.95±1.00 | 5.07±1.01 | 4.99±1.34 | 4.96±1.09 | 182.84b | <0.001 |
| hs-CRP[M(P25,P75),mg/L] | 0.57(0.20,1.70) | 0.70(0.28,1.91) | 0.89(0.34,2.30) | 1.07(0.42,2.70) | 0.80(0.30,2.15) | 20.40c | <0.001 |
| CMI分组 | 事件/总例数 | 发病率(%) | 发病密度(/千人年) | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| Q1组 | 4 137/19 545 | 21.17 | 16.61 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 5 090/19 907 | 25.57 | 20.82 | 1.24(1.19~1.29) | <0.001 | 1.12(1.07~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 |
| Q3组 | 5 289/19 227 | 27.51 | 22.70 | 1.32(1.27~1.38) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 6 123/19 436 | 31.50 | 26.83 | 1.58(1.52~1.65) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
Table 2 Cox proportional hazard models regression analysis of CMI exposure level and CKD risk
| CMI分组 | 事件/总例数 | 发病率(%) | 发病密度(/千人年) | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| Q1组 | 4 137/19 545 | 21.17 | 16.61 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 5 090/19 907 | 25.57 | 20.82 | 1.24(1.19~1.29) | <0.001 | 1.12(1.07~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 |
| Q3组 | 5 289/19 227 | 27.51 | 22.70 | 1.32(1.27~1.38) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 6 123/19 436 | 31.50 | 26.83 | 1.58(1.52~1.65) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 分层 | 例数 | CMI四分位组 | 模型1 | 模型2 | 模型3 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| 饮酒 | <0.001 | ||||||||
| 是 | 30 770 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.14~1.32) | <0.001 | 1.13(1.05~1.22) | 0.001 | 1.13(1.05~1.22) | 0.001 | |||
| Q3组 | 1.35(1.26~1.45) | <0.001 | 1.19(1.10~1.28) | <0.001 | 1.19(1.11~1.28) | <0.001 | |||
| Q4组 | 1.71(1.60~1.83) | <0.001 | 1.46(1.36~1.58) | <0.001 | 1.46(1.36~1.58) | <0.001 | |||
| 否 | 47 345 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.22(1.16~1.28) | <0.001 | 1.11(1.05~1.16) | 0.001 | 1.10(1.05~1.16) | 0.001 | |||
| Q3组 | 1.29(1.23~1.36) | <0.001 | 1.14(1.08~1.20) | <0.001 | 1.14(1.08~1.20) | <0.001 | |||
| Q4组 | 1.50(1.43~1.57) | <0.001 | 1.26(1.20~1.33) | <0.001 | 1.27(1.20~1.33) | <0.001 | |||
| 吸烟 | 0.001 | ||||||||
| 是 | 27 905 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.14~1.33) | <0.001 | 1.14(1.06~1.23) | 0.001 | 1.14(1.06~1.23) | 0.001 | |||
| Q3组 | 1.30(1.20~1.39) | <0.001 | 1.16(1.07~1.25) | 0.001 | 1.16(1.07~1.25) | 0.001 | |||
| Q4组 | 1.70(1.60~1.82) | <0.001 | 1.46(1.35~1.58) | <0.001 | 1.46(1.36~1.58) | <0.001 | |||
| 否 | 50 210 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.17~1.29) | <0.001 | 1.10(1.05~1.16) | <0.001 | 1.10(1.05~1.16) | <0.001 | |||
| Q3组 | 1.33(1.26~1.39) | <0.001 | 1.16(1.10~1.22) | <0.001 | 1.16(1.10~1.22) | <0.001 | |||
| Q4组 | 1.52(1.45~1.59) | <0.001 | 1.27(1.21~1.34) | <0.001 | 1.28(1.21~1.34) | <0.001 | |||
Table 3 Stratified analysis of smoking status and alcohol consumption
| 分层 | 例数 | CMI四分位组 | 模型1 | 模型2 | 模型3 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| 饮酒 | <0.001 | ||||||||
| 是 | 30 770 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.14~1.32) | <0.001 | 1.13(1.05~1.22) | 0.001 | 1.13(1.05~1.22) | 0.001 | |||
| Q3组 | 1.35(1.26~1.45) | <0.001 | 1.19(1.10~1.28) | <0.001 | 1.19(1.11~1.28) | <0.001 | |||
| Q4组 | 1.71(1.60~1.83) | <0.001 | 1.46(1.36~1.58) | <0.001 | 1.46(1.36~1.58) | <0.001 | |||
| 否 | 47 345 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.22(1.16~1.28) | <0.001 | 1.11(1.05~1.16) | 0.001 | 1.10(1.05~1.16) | 0.001 | |||
| Q3组 | 1.29(1.23~1.36) | <0.001 | 1.14(1.08~1.20) | <0.001 | 1.14(1.08~1.20) | <0.001 | |||
| Q4组 | 1.50(1.43~1.57) | <0.001 | 1.26(1.20~1.33) | <0.001 | 1.27(1.20~1.33) | <0.001 | |||
| 吸烟 | 0.001 | ||||||||
| 是 | 27 905 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.14~1.33) | <0.001 | 1.14(1.06~1.23) | 0.001 | 1.14(1.06~1.23) | 0.001 | |||
| Q3组 | 1.30(1.20~1.39) | <0.001 | 1.16(1.07~1.25) | 0.001 | 1.16(1.07~1.25) | 0.001 | |||
| Q4组 | 1.70(1.60~1.82) | <0.001 | 1.46(1.35~1.58) | <0.001 | 1.46(1.36~1.58) | <0.001 | |||
| 否 | 50 210 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.17~1.29) | <0.001 | 1.10(1.05~1.16) | <0.001 | 1.10(1.05~1.16) | <0.001 | |||
| Q3组 | 1.33(1.26~1.39) | <0.001 | 1.16(1.10~1.22) | <0.001 | 1.16(1.10~1.22) | <0.001 | |||
| Q4组 | 1.52(1.45~1.59) | <0.001 | 1.27(1.21~1.34) | <0.001 | 1.28(1.21~1.34) | <0.001 | |||
| 分层 | 例数 | CMI四分位组 | 模型1 | 模型2 | 模型3 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| 性别 | 0.078 | ||||||||
| 男 | 62 305 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.24(1.18~1.30) | <0.001 | 1.12(1.07~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 | |||
| Q3组 | 1.32(1.26~1.38) | <0.001 | 1.16(1.10~1.21) | <0.001 | 1.16(1.10~1.21) | <0.001 | |||
| Q4组 | 1.60(1.53~1.67) | <0.001 | 1.34(1.27~1.41) | <0.001 | 1.34(1.27~1.41) | <0.001 | |||
| 女 | 15 810 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.27(1.17~1.37) | <0.001 | 1.15(1.06~1.25) | 0.001 | 1.15(1.06~1.25) | 0.001 | |||
| Q3组 | 1.37(1.26~1.49) | <0.001 | 1.19(1.09~1.30) | 0.001 | 1.19(1.09~1.30) | 0.001 | |||
| Q4组 | 1.59(1.45~1.73) | <0.001 | 1.35(1.23~1.48) | <0.001 | 1.35(1.23~1.48) | <0.001 | |||
| 年龄 | 0.686 | ||||||||
| <60岁 | 64 323 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.26(1.20~1.32) | <0.001 | 1.13(1.08~1.19) | <0.001 | 1.13(1.08~1.19) | <0.001 | |||
| Q3组 | 1.34(1.28~1.40) | <0.001 | 1.17(1.11~1.23) | <0.001 | 1.17(1.11~1.23) | <0.001 | |||
| Q4组 | 1.60(1.53~1.68) | <0.001 | 1.35(1.29~1.42) | <0.001 | 1.36(1.29~1.43) | <0.001 | |||
| ≥60岁 | 13 792 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.13~1.33) | <0.001 | 1.13(1.04~1.23) | 0.004 | 1.13(1.04~1.23) | 0.005 | |||
| Q3组 | 1.34(1.24~1.45) | <0.001 | 1.20(1.10~1.31) | <0.001 | 1.20(1.10~1.30) | <0.001 | |||
| Q4组 | 1.65(1.52~1.79) | <0.001 | 1.41(1.29~1.53) | <0.001 | 1.40(1.29~1.53) | <0.001 | |||
Table 4 Stratified analysis of age and gender
| 分层 | 例数 | CMI四分位组 | 模型1 | 模型2 | 模型3 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| 性别 | 0.078 | ||||||||
| 男 | 62 305 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.24(1.18~1.30) | <0.001 | 1.12(1.07~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 | |||
| Q3组 | 1.32(1.26~1.38) | <0.001 | 1.16(1.10~1.21) | <0.001 | 1.16(1.10~1.21) | <0.001 | |||
| Q4组 | 1.60(1.53~1.67) | <0.001 | 1.34(1.27~1.41) | <0.001 | 1.34(1.27~1.41) | <0.001 | |||
| 女 | 15 810 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.27(1.17~1.37) | <0.001 | 1.15(1.06~1.25) | 0.001 | 1.15(1.06~1.25) | 0.001 | |||
| Q3组 | 1.37(1.26~1.49) | <0.001 | 1.19(1.09~1.30) | 0.001 | 1.19(1.09~1.30) | 0.001 | |||
| Q4组 | 1.59(1.45~1.73) | <0.001 | 1.35(1.23~1.48) | <0.001 | 1.35(1.23~1.48) | <0.001 | |||
| 年龄 | 0.686 | ||||||||
| <60岁 | 64 323 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.26(1.20~1.32) | <0.001 | 1.13(1.08~1.19) | <0.001 | 1.13(1.08~1.19) | <0.001 | |||
| Q3组 | 1.34(1.28~1.40) | <0.001 | 1.17(1.11~1.23) | <0.001 | 1.17(1.11~1.23) | <0.001 | |||
| Q4组 | 1.60(1.53~1.68) | <0.001 | 1.35(1.29~1.42) | <0.001 | 1.36(1.29~1.43) | <0.001 | |||
| ≥60岁 | 13 792 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.23(1.13~1.33) | <0.001 | 1.13(1.04~1.23) | 0.004 | 1.13(1.04~1.23) | 0.005 | |||
| Q3组 | 1.34(1.24~1.45) | <0.001 | 1.20(1.10~1.31) | <0.001 | 1.20(1.10~1.30) | <0.001 | |||
| Q4组 | 1.65(1.52~1.79) | <0.001 | 1.41(1.29~1.53) | <0.001 | 1.40(1.29~1.53) | <0.001 | |||
| 分层 | 例数 | CMI四分位组 | 模型1 | 模型2 | 模型3 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| BMI | 0.201 | ||||||||
| ≥28 kg/m2 | 9 985 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.14(0.98~1.31) | 0.089 | 1.04(0.90~1.20) | 0.612 | 1.03(0.90~1.20) | <0.001 | |||
| Q3组 | 1.18(1.02~1.35) | 0.018 | 1.07(0.93~1.22) | 0.374 | 1.06(0.93~1.22) | <0.001 | |||
| Q4组 | 1.45(1.27~1.65) | <0.001 | 1.30(1.13~1.49) | 0.000 | 1.30(1.36~1.58) | <0.001 | |||
| <28 kg/m2 | 68 130 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.22(1.17~1.27) | <0.001 | 1.14(1.09~1.19) | <0.001 | 1.14(1.09~1.19) | 0.016 | |||
| Q3组 | 1.28(1.23~1.34) | <0.001 | 1.18(1.13~1.23) | <0.001 | 1.18(1.13~1.23) | 0.000 | |||
| Q4组 | 1.49(1.43~1.56) | <0.001 | 1.33(1.27~1.40) | <0.001 | 1.33(1.27~1.40) | <0.001 | |||
| 高血压 | 0.447 | ||||||||
| 是 | 31 065 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.14(1.07~1.21) | <0.001 | 1.08(1.02~1.15) | 0.016 | 1.08(1.02~1.15) | <0.001 | |||
| Q3组 | 1.20(1.13~1.28) | <0.001 | 1.12(1.06~1.20) | 0.000 | 1.12(1.05~1.20) | <0.001 | |||
| Q4组 | 1.42(1.34~1.50) | <0.001 | 1.30(1.22~1.38) | <0.001 | 1.30(1.22~1.38) | <0.001 | |||
| 否 | 47 050 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.22(1.15~1.29) | <0.001 | 1.15(1.09~1.22) | <0.001 | 1.15(1.09~1.22) | 0.735 | |||
| Q3组 | 1.26(1.20~1.34) | <0.001 | 1.20(1.13~1.27) | <0.001 | 1.20(1.13~1.27) | 0.407 | |||
| Q4组 | 1.46(1.38~1.54) | <0.001 | 1.37(1.29~1.46) | <0.001 | 1.37(1.29~1.46) | 0.005 | |||
| 糖尿病 | 0.164 | ||||||||
| 是 | 6 422 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.10(0.86~1.17) | 0.965 | 0.97(0.83~1.13) | 0.695 | 0.97(0.84~1.14) | <0.001 | |||
| Q3组 | 1.12(0.97~1.29) | 0.123 | 1.06(0.92~1.23) | 0.429 | 1.06(0.92~1.23) | <0.001 | |||
| Q4组 | 1.31(1.14~1.50) | <0.001 | 1.22(1.05~1.40) | 0.007 | 1.23(1.06~1.41) | <0.001 | |||
| 否 | 71 693 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.24(1.19~1.29) | <0.001 | 1.13(1.09~1.18) | <0.001 | 1.13(1.09~1.18) | <0.001 | |||
| Q3组 | 1.31(1.25~1.36) | <0.001 | 1.17(1.12~1.22) | <0.001 | 1.17(1.12~1.22) | <0.001 | |||
| Q4组 | 1.54(1.48~1.61) | <0.001 | 1.35(1.29~1.41) | <0.001 | 1.35(1.29~1.41) | <0.001 | |||
Table 5 Stratified analysis of BMI, hypertension, and diabetes status
| 分层 | 例数 | CMI四分位组 | 模型1 | 模型2 | 模型3 | P交互值 | |||
|---|---|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||||
| BMI | 0.201 | ||||||||
| ≥28 kg/m2 | 9 985 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.14(0.98~1.31) | 0.089 | 1.04(0.90~1.20) | 0.612 | 1.03(0.90~1.20) | <0.001 | |||
| Q3组 | 1.18(1.02~1.35) | 0.018 | 1.07(0.93~1.22) | 0.374 | 1.06(0.93~1.22) | <0.001 | |||
| Q4组 | 1.45(1.27~1.65) | <0.001 | 1.30(1.13~1.49) | 0.000 | 1.30(1.36~1.58) | <0.001 | |||
| <28 kg/m2 | 68 130 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.22(1.17~1.27) | <0.001 | 1.14(1.09~1.19) | <0.001 | 1.14(1.09~1.19) | 0.016 | |||
| Q3组 | 1.28(1.23~1.34) | <0.001 | 1.18(1.13~1.23) | <0.001 | 1.18(1.13~1.23) | 0.000 | |||
| Q4组 | 1.49(1.43~1.56) | <0.001 | 1.33(1.27~1.40) | <0.001 | 1.33(1.27~1.40) | <0.001 | |||
| 高血压 | 0.447 | ||||||||
| 是 | 31 065 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.14(1.07~1.21) | <0.001 | 1.08(1.02~1.15) | 0.016 | 1.08(1.02~1.15) | <0.001 | |||
| Q3组 | 1.20(1.13~1.28) | <0.001 | 1.12(1.06~1.20) | 0.000 | 1.12(1.05~1.20) | <0.001 | |||
| Q4组 | 1.42(1.34~1.50) | <0.001 | 1.30(1.22~1.38) | <0.001 | 1.30(1.22~1.38) | <0.001 | |||
| 否 | 47 050 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.22(1.15~1.29) | <0.001 | 1.15(1.09~1.22) | <0.001 | 1.15(1.09~1.22) | 0.735 | |||
| Q3组 | 1.26(1.20~1.34) | <0.001 | 1.20(1.13~1.27) | <0.001 | 1.20(1.13~1.27) | 0.407 | |||
| Q4组 | 1.46(1.38~1.54) | <0.001 | 1.37(1.29~1.46) | <0.001 | 1.37(1.29~1.46) | 0.005 | |||
| 糖尿病 | 0.164 | ||||||||
| 是 | 6 422 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.10(0.86~1.17) | 0.965 | 0.97(0.83~1.13) | 0.695 | 0.97(0.84~1.14) | <0.001 | |||
| Q3组 | 1.12(0.97~1.29) | 0.123 | 1.06(0.92~1.23) | 0.429 | 1.06(0.92~1.23) | <0.001 | |||
| Q4组 | 1.31(1.14~1.50) | <0.001 | 1.22(1.05~1.40) | 0.007 | 1.23(1.06~1.41) | <0.001 | |||
| 否 | 71 693 | Q1组 | 1.00 | 1.00 | 1.00 | ||||
| Q2组 | 1.24(1.19~1.29) | <0.001 | 1.13(1.09~1.18) | <0.001 | 1.13(1.09~1.18) | <0.001 | |||
| Q3组 | 1.31(1.25~1.36) | <0.001 | 1.17(1.12~1.22) | <0.001 | 1.17(1.12~1.22) | <0.001 | |||
| Q4组 | 1.54(1.48~1.61) | <0.001 | 1.35(1.29~1.41) | <0.001 | 1.35(1.29~1.41) | <0.001 | |||
| 分析 | 事件数/总例数 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 排除高血压 | 9 957/47 050 | ||||||
| Q1组 | 2 523/14 124 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 2 621/12 324 | 1.22(1.16~1.29) | <0.001 | 1.15(1.09~1.22) | <0.001 | 1.15(1.09~1.22) | <0.001 |
| Q3组 | 2 385/10 790 | 1.27(1.20~1.34) | <0.001 | 1.19(1.13~1.27) | <0.001 | 1.19(1.13~1.27) | <0.001 |
| Q4组 | 2 428/9 812 | 1.46(1.38~1.55) | <0.001 | 1.37(1.29~1.46) | <0.001 | 1.37(1.29~1.46) | <0.001 |
| 排除糖尿病 | 18 185/71 693 | ||||||
| Q1组 | 3 871/18 765 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 4 637/18 592 | 1.24(1.19~1.30) | <0.001 | 1.13(1.08~1.18) | <0.001 | 1.13(1.08~1.18) | <0.001 |
| Q3组 | 4 626/17 464 | 1.31(1.25~1.37) | <0.001 | 1.17(1.12~1.22) | <0.001 | 1.17(1.12~1.22) | <0.001 |
| Q4组 | 5 051/16 872 | 1.54(1.48~1.61) | <0.001 | 1.35(1.29~1.41) | <0.001 | 1.35(1.29~1.41) | <0.001 |
| 排除降压药 | 18 071/71 195 | ||||||
| Q1组 | 3 832/18 592 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 4 610/18 451 | 1.25(1.19~1.30) | <0.001 | 1.14(1.09~1.19) | <0.001 | 1.14(1.09~1.19) | <0.001 |
| Q3组 | 4 536/17 189 | 1.31(1.25~1.36) | <0.001 | 1.17(1.12~1.22) | <0.001 | 1.17(1.12~1.22) | <0.001 |
| Q4组 | 5 093/16 963 | 1.55(1.48~1.62) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 排除降糖药 | 19 970/76 519 | ||||||
| Q1组 | 4 048/19 322 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 4 978/19 581 | 1.24(1.19~1.30) | <0.001 | 1.13(1.08~1.18) | <0.001 | 1.13(1.08~1.18) | <0.001 |
| Q3组 | 5 086/18 747 | 1.31(1.26~1.37) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 5 858/18 869 | 1.57(1.51~1.64) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 排除调脂药 | 20 416/77 476 | ||||||
| Q1组 | 4 112/19 461 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 5 050/19 773 | 1.24(1.19~1.29) | <0.001 | 1.12(1.08~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 |
| Q3组 | 5 228/19 058 | 1.32(1.26~1.37) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 6 026/19 184 | 1.58(1.51~1.64) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 死亡竞争风险 | 20 639/78 115 | ||||||
| Q1组 | 4 137/19 545 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 5 090/19 907 | 1.24(1.19~1.29) | <0.001 | 1.12(1.07~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 |
| Q3组 | 5 289/19 227 | 1.32(1.27~1.38) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 6 123/19 436 | 1.58(1.52~1.65) | <0.001 | 1.33(1.28~1.39) | <0.001 | 1.34(1.28~1.39) | <0.001 |
Table 6 Sensitivity analysis and death competition risk analysis of CMI exposure level and CKD risk
| 分析 | 事件数/总例数 | 模型1 | 模型2 | 模型3 | |||
|---|---|---|---|---|---|---|---|
| HR(95%CI) | P值 | HR(95%CI) | P值 | HR(95%CI) | P值 | ||
| 排除高血压 | 9 957/47 050 | ||||||
| Q1组 | 2 523/14 124 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 2 621/12 324 | 1.22(1.16~1.29) | <0.001 | 1.15(1.09~1.22) | <0.001 | 1.15(1.09~1.22) | <0.001 |
| Q3组 | 2 385/10 790 | 1.27(1.20~1.34) | <0.001 | 1.19(1.13~1.27) | <0.001 | 1.19(1.13~1.27) | <0.001 |
| Q4组 | 2 428/9 812 | 1.46(1.38~1.55) | <0.001 | 1.37(1.29~1.46) | <0.001 | 1.37(1.29~1.46) | <0.001 |
| 排除糖尿病 | 18 185/71 693 | ||||||
| Q1组 | 3 871/18 765 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 4 637/18 592 | 1.24(1.19~1.30) | <0.001 | 1.13(1.08~1.18) | <0.001 | 1.13(1.08~1.18) | <0.001 |
| Q3组 | 4 626/17 464 | 1.31(1.25~1.37) | <0.001 | 1.17(1.12~1.22) | <0.001 | 1.17(1.12~1.22) | <0.001 |
| Q4组 | 5 051/16 872 | 1.54(1.48~1.61) | <0.001 | 1.35(1.29~1.41) | <0.001 | 1.35(1.29~1.41) | <0.001 |
| 排除降压药 | 18 071/71 195 | ||||||
| Q1组 | 3 832/18 592 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 4 610/18 451 | 1.25(1.19~1.30) | <0.001 | 1.14(1.09~1.19) | <0.001 | 1.14(1.09~1.19) | <0.001 |
| Q3组 | 4 536/17 189 | 1.31(1.25~1.36) | <0.001 | 1.17(1.12~1.22) | <0.001 | 1.17(1.12~1.22) | <0.001 |
| Q4组 | 5 093/16 963 | 1.55(1.48~1.62) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 排除降糖药 | 19 970/76 519 | ||||||
| Q1组 | 4 048/19 322 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 4 978/19 581 | 1.24(1.19~1.30) | <0.001 | 1.13(1.08~1.18) | <0.001 | 1.13(1.08~1.18) | <0.001 |
| Q3组 | 5 086/18 747 | 1.31(1.26~1.37) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 5 858/18 869 | 1.57(1.51~1.64) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 排除调脂药 | 20 416/77 476 | ||||||
| Q1组 | 4 112/19 461 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 5 050/19 773 | 1.24(1.19~1.29) | <0.001 | 1.12(1.08~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 |
| Q3组 | 5 228/19 058 | 1.32(1.26~1.37) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 6 026/19 184 | 1.58(1.51~1.64) | <0.001 | 1.34(1.28~1.40) | <0.001 | 1.34(1.28~1.40) | <0.001 |
| 死亡竞争风险 | 20 639/78 115 | ||||||
| Q1组 | 4 137/19 545 | 1.00 | 1.00 | 1.00 | |||
| Q2组 | 5 090/19 907 | 1.24(1.19~1.29) | <0.001 | 1.12(1.07~1.17) | <0.001 | 1.12(1.07~1.17) | <0.001 |
| Q3组 | 5 289/19 227 | 1.32(1.27~1.38) | <0.001 | 1.16(1.11~1.21) | <0.001 | 1.16(1.11~1.21) | <0.001 |
| Q4组 | 6 123/19 436 | 1.58(1.52~1.65) | <0.001 | 1.33(1.28~1.39) | <0.001 | 1.34(1.28~1.39) | <0.001 |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
李幸,杨毅宁. 新疆地区高尿酸血症患病现状及其与心脏代谢指数的相关性研究[J]. 中国全科医学, 2024, 27(9): 1095-1101.
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [1] | XUE Cuirong, WEI Wei, WU Renyuan, XUE Yaqin, XU Huijiang, LYU Weijiang, JIANG Dandan. Prevalence and Management Status of Chronic Kidney Disease in Hypertensive and Type 2 Diabetic Populations: a Community-based Cross-sectional Study [J]. Chinese General Practice, 2026, 29(25): 3650-3654. |
| [2] | LI Xiaoxue, YIN Lihua, SU Xu, ZHANG Fuyan, ZHAN Qingqing, AN Qinyu, WANG Huiqun, LIU Tao, TAN Shisheng. Association between Dietary Quality and Risk of Hypertension: a Study Based on the 2022 Version of the Chinese Dietary Balance Index [J]. Chinese General Practice, 2026, 29(25): 3631-3639. |
| [3] | ZHANG Xuechao, QI Qi, WU Xinyu, HAN Quanle, LI Lei, DENG Jie, LI Cangtuo, YUE Bocheng, WU Shouling, LI Kangbo. Association between the Atherogenic Index of Plasma and New-onset Chronic Kidney Disease [J]. Chinese General Practice, 2026, 29(24): 3440-3446. |
| [4] | ZHANG Wenzheng, ZHANG Hongling. Association between Cardiometabolic Index and Hypertension in Elderly Patients with Metabolic Associated Fatty Liver Disease in the Community Population: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(23): 3261-3267. |
| [5] | QU Furong, ZHAO Lijun, ZENG Xiaoxi, LI Jing, LI Sheyu. Interpretation of BMJ Clinical Practice Guideline: SGLT-2 Inhibitors for Adults with Chronic Kidney Disease [J]. Chinese General Practice, 2026, 29(22): 3079-3085. |
| [6] | CHAI Zhihao, ZHANG Weisen, LUO Jiaoling, ZHU Feng, ZHU Tong, JIN Yali, PAN Jing, LU Yingjun, JIANG Chaoqiang. The Mediation Effect of Socioeconomic Status in Childhood Parental Literacy and Cognitive Function in Middle-aged and Older People: Based on Guangzhou Biobank Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2959-2966. |
| [7] | HAN Congcong, QIU Xinyu, SHAN Chunfang, SONG Ning, CHEN Qingjie, MULADILI· Abudureheman, LI Xiaomei, YANG Yining, ZHAO Qian. Impact of Metabolic Obesity Phenotype on Long-term Prognosis after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2026, 29(21): 2950-2958. |
| [8] | LIU Shuai, YUAN Shizhao, LIU Yan, JIA Shuoxian, ZHAO Yan, WANG Ziyi, ZHOU Chunhua, YU Jing. Evaluation of the Efficacy, Safetyand Economy of Different Amphotericin B Formulationsin Invasive Fungal Disease: a Retrospective Cohort Study [J]. Chinese General Practice, 2026, 29(21): 2967-2974. |
| [9] | REYILAI· Maimaiti, ZHOU Yiran, WU Yun, LIU Zhencheng, LU Yaoqin, WU Haiyan. Association between Novel Obesity Indicators and Cardiovascular Disease Risk in Hypertensive Patients [J]. Chinese General Practice, 2026, 29(20): 2836-2845. |
| [10] | QIU Xinyu, ZHAO Qian, CHEN Yufei, JIAMULE· Maimaitiyiming, HAN Congcong, AIKEDAN· Aierken, LI Xiaomei, YANG Yining. Weight Status and Metabolic Characteristics on the Longitudinal Trajectory of Systolic Blood Pressure: a Cohort Study [J]. Chinese General Practice, 2026, 29(15): 2006-2013. |
| [11] | DUAN Ruolan, QIU Jiamei, YANG Changyuan, LI Qin, MO Haoyu, PI Minhui, YANG Zhenhua, XIA Ai, ZHANG La, LIU Xusheng, LU Fuhua, HOU Haijing, SU Guobin. Assessment of Fatigue in Patients with Chronic Kidney Disease: the Choice of Patient-reported Outcome Measures Scales [J]. Chinese General Practice, 2026, 29(13): 1784-1792. |
| [12] | LIU Xiang, CHEN Hong, CUI Rui, GUO Zhichao, LI Panpan, CAO Zilong, JI Yiqing, YU Wenya. Consistencies and Differences in Early Childhood Development Characteristics in Megacities: a Retrospective Cohort Study [J]. Chinese General Practice, 2026, 29(11): 1411-1421. |
| [13] | LI Qiuchun, SU Ping, PANG Jinhong, CHEN Qiaoqiao, ZHAO Yingying, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association of Triglyceride Glucose Index with Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 Population: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(09): 1129-1136. |
| [14] | ZHANG Rui, WANG Weiqiang, LU Hongrun, ZHAO Yu, LI Jiazhen. Correlation between the Continuous Metabolic Syndrome Score and Glomerular Filtration Rate in Individuals Aged 60 and Above [J]. Chinese General Practice, 2026, 29(07): 879-884. |
| [15] | ZHAO Qianqian, ZHANG Mei, LI Yanying, ZHANG Yanhong, YAN Wenhua, PAN Hui, BAN Bo. Clinical Characteristics of Growth Hormone Deficiency and Analysis of the Efficacy of Recombinant Human Growth Hormone: a Ten-year Longitudinal Cohort Study [J]. Chinese General Practice, 2026, 29(06): 733-740. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||